Charge-conversional PLGA nanoparticle to active deliver chemotherapy drug to tumor

• 作 者: Jiang-boDu;Dao-zhouLiu;Bang-leZhang;Si-yuanZhou;
• 机 构: Department of Pharmaceutics,School of Pharmacy,Fourth Military Medical University,Xi'an,710032,Chin
• 出 处: 2014年中国药物制剂大会——中国药学会药剂专业委员会年会、第六届亚洲阿登制药技术研讨会暨国际控释协会中国分会年会
• 发表日期: 2014年期

　　Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are widely used in tumor targeted drug delivery system owing to its non immunogenicity and biodegradable characteristics.However, the naked PLGA nanoparticles not only have low drug loading but also can be rapidly removed from blood circulation by the immune system.Therefore, the aim of this study was to focus on the preparation of both active and passive tumor targeting lipid hybrid PLGA nanoparticles (LNPs) to enhance drug loading and drug delivery efficiency.